Initiator Pharma A/S (STO:INIT)

Market Cap	213.40M
Revenue (ttm)	n/a
Net Income (ttm)	-16.67M
Shares Out	56.16M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	5.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,483
Average Volume	141,396
Open	3.760
Previous Close	3.800
Day's Range	3.760 - 4.050
52-Week Range	3.550 - 11.100
Beta	0.21
RSI	32.04
Earnings Date	Aug 22, 2025

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: INIT

Financial Performance

Financial numbers in DKK